AU2013225633B2 - Ingenol derivatives in the reactivation of latent HIV - Google Patents

Ingenol derivatives in the reactivation of latent HIV Download PDF

Info

Publication number
AU2013225633B2
AU2013225633B2 AU2013225633A AU2013225633A AU2013225633B2 AU 2013225633 B2 AU2013225633 B2 AU 2013225633B2 AU 2013225633 A AU2013225633 A AU 2013225633A AU 2013225633 A AU2013225633 A AU 2013225633A AU 2013225633 B2 AU2013225633 B2 AU 2013225633B2
Authority
AU
Australia
Prior art keywords
ingenol
formula
derivatives
cells
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013225633A
Other languages
English (en)
Other versions
AU2013225633A1 (en
Inventor
Luiz Francisco Pianowski
Amilcar Tanuri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amazonia Fitomedicamentos Ltda
Original Assignee
Amazonia Fitomedicamentos Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from BR102012004739A external-priority patent/BR102012004739A2/pt
Priority claimed from BR102012006549A external-priority patent/BR102012006549A2/pt
Application filed by Amazonia Fitomedicamentos Ltda filed Critical Amazonia Fitomedicamentos Ltda
Publication of AU2013225633A1 publication Critical patent/AU2013225633A1/en
Application granted granted Critical
Publication of AU2013225633B2 publication Critical patent/AU2013225633B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G8/00—Condensation polymers of aldehydes or ketones with phenols only
    • C08G8/28—Chemically modified polycondensates
    • C08G8/30—Chemically modified polycondensates by unsaturated compounds, e.g. terpenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2013225633A 2012-03-02 2013-03-01 Ingenol derivatives in the reactivation of latent HIV Ceased AU2013225633B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
BRBR1020120047390 2012-03-02
BR102012004739A BR102012004739A2 (pt) 2012-03-02 2012-03-02 uso de um ou mais derivados de ingenol, associação farmacêutica, composição farmacêutica, adjuvante, método de travamento e método para a reativação do vírus hiv latente
BR102012006549A BR102012006549A2 (pt) 2012-03-23 2012-03-23 uso de um ou mais derivados de ingenol, associação farmacêutica, composição farmacêutica, adjuvante, método de tratamento e método para a reativação do vírus hiv latente
BRBR1020120065495 2012-03-23
PCT/BR2013/000063 WO2013126980A1 (pt) 2012-03-02 2013-03-01 Derivados de ingenol na reativação de vírus hiv latente

Publications (2)

Publication Number Publication Date
AU2013225633A1 AU2013225633A1 (en) 2014-08-28
AU2013225633B2 true AU2013225633B2 (en) 2017-11-23

Family

ID=49081479

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013225633A Ceased AU2013225633B2 (en) 2012-03-02 2013-03-01 Ingenol derivatives in the reactivation of latent HIV

Country Status (13)

Country Link
US (1) US10105339B2 (enExample)
EP (1) EP2821105B1 (enExample)
JP (1) JP6280510B2 (enExample)
CN (1) CN104136081B (enExample)
AU (1) AU2013225633B2 (enExample)
CA (1) CA2864995C (enExample)
ES (1) ES2683726T3 (enExample)
IL (1) IL234404A (enExample)
IN (1) IN2014MN01911A (enExample)
MX (1) MX359300B (enExample)
NZ (1) NZ628408A (enExample)
RU (1) RU2609512C2 (enExample)
WO (1) WO2013126980A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102012028120B8 (pt) * 2012-11-01 2022-08-02 Amazonia Fitomedicamentos Ltda Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
WO2016022358A1 (en) 2014-08-08 2016-02-11 The Regents Of The University Of California Compositions and methods for reactivating latent viral infections
WO2016177833A1 (en) 2015-05-04 2016-11-10 Bionor Immuno As Dosage regimen for hiv vaccine
WO2016191836A1 (pt) * 2015-06-03 2016-12-08 Amazônia Fitomedicamentos Ltda. Método de preparação de ingenol-3-dodecanoato, método de preparação de 3-etinil-3-hidroxi-4.7.7-trimetilbiciclo[4.1.0]heptano-2-carbaldeído e método de preparação de 2,2-dimetil-4-etinil-5-trifenilfosforanilideno-1,3-dioxano
WO2016191837A1 (pt) * 2015-06-03 2016-12-08 Amazônia Fitomedicamentos Ltda. Método de preparação de ingenol-3-hexanoato, método de preparação de 3-etinil-3-hidroxi-4.7.7-trimetilbiciclo[4.1.0]heptano-2-carbaldeído e método de preparação do composto 2,2-dimetil-4-etinil-5-trifenilfosforanilideno-1,3-dioxano
CN105079323B (zh) * 2015-09-15 2019-08-23 北京工业大学 几种中药提取物在hiv潜伏再激活治疗中的应用
CN106928063B (zh) * 2015-12-31 2020-09-01 上海鑫昊生物科技有限公司 巨大戟二萜醇类化合物及其在抗hiv潜伏治疗上的应用
WO2017130156A1 (en) 2016-01-27 2017-08-03 Glaxosmithkline Intellectual Property (No.2) Limited Ingenol analogs, pharmaceutical compositions and methods of use thereof
CN109912419A (zh) * 2017-12-13 2019-06-21 复旦大学 巨大戟烷型二萜及其在制备抗艾滋病毒药物中的用途
CN110251495B (zh) * 2018-03-12 2022-05-31 重庆医科大学 20-脱氧巨大戟二萜醇在制备抑制hbv复制的药物中的应用
BR112021014721A2 (pt) * 2019-01-28 2021-12-21 The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone Ligantes de nkg2d não naturais modificados que liberam seletivamente moléculas heterólogas ligadas a receptores de nkg2d não naturais em células car

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116897A1 (fr) * 2005-04-30 2006-11-09 Nihon University Diterpenes provenant de euphorbia kansui et leur utilisation
WO2011086423A1 (en) * 2010-01-15 2011-07-21 Amazonia Fitomedicamentos Ltda Pharmaceutical use of multicyclic compounds as anti-aids agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07165600A (ja) 1993-10-18 1995-06-27 Souyaku Gijutsu Kenkyusho:Kk 抗ウイルス剤
JP2003171349A (ja) * 2001-08-06 2003-06-20 Univ Nihon 新規なジテルペン類、及びこれを用いた組成物、抗炎症剤、抗癌剤
BRPI0520394A2 (pt) * 2005-06-28 2009-05-05 Amazonia Fitomedicamentos Ltda fração ativa de um extrato de látex de euphorbia tirucalli l. com um solvente polar, uso de um ativo de um extrato de euphorbia tirucalli l. com solvente polar, uso de um ou mais compostos de 3-(2,4,6-dodecatrienoil)-ingenol e 3-(2,4,6,8-tetradecatetranoil)-ingenol, composição , uso da composição e processo para obtenção de uma fração ativa de um extrato de euphorbia tirucalli l. com solvente polar
BRPI0810806A2 (pt) 2007-04-30 2014-10-29 Peplin Research Pty Ltd Método para tratar uma lesão cutânea em um indivíduo
WO2011086424A1 (en) 2010-01-15 2011-07-21 Amazonia Fitomedicamentos Ltda Pharmaceutical use of multicyclic compounds mixtures as concomitant anti-cancer, anti-inflammatory and anti-pain agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116897A1 (fr) * 2005-04-30 2006-11-09 Nihon University Diterpenes provenant de euphorbia kansui et leur utilisation
WO2011086423A1 (en) * 2010-01-15 2011-07-21 Amazonia Fitomedicamentos Ltda Pharmaceutical use of multicyclic compounds as anti-aids agents

Also Published As

Publication number Publication date
CN104136081A (zh) 2014-11-05
HK1203872A1 (en) 2015-11-06
MX359300B (es) 2018-09-21
CA2864995C (en) 2016-12-06
IN2014MN01911A (enExample) 2015-07-10
JP6280510B2 (ja) 2018-02-14
CN104136081B (zh) 2018-05-15
EP2821105A4 (en) 2015-11-04
EP2821105A8 (en) 2015-04-29
CA2864995A1 (en) 2013-09-06
AU2013225633A1 (en) 2014-08-28
NZ628408A (en) 2017-09-29
IL234404A (en) 2017-09-28
EP2821105A1 (en) 2015-01-07
US20150030638A1 (en) 2015-01-29
MX2014010463A (es) 2014-10-13
EP2821105B1 (en) 2018-05-23
RU2609512C2 (ru) 2017-02-02
RU2014139825A (ru) 2016-04-20
WO2013126980A1 (pt) 2013-09-06
ES2683726T3 (es) 2018-09-27
JP2015508782A (ja) 2015-03-23
US10105339B2 (en) 2018-10-23

Similar Documents

Publication Publication Date Title
AU2013225633B2 (en) Ingenol derivatives in the reactivation of latent HIV
JP6804790B1 (ja) Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
KR101830715B1 (ko) Hiv 감염을 치료하기 위한 약학적 조합물
CA3087192A1 (en) Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents
EP2830629A1 (en) Compositions and methods for reactivating latent immunodeficiency virus
US11718637B2 (en) Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same
EP4192474B1 (en) Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
WO2020007070A1 (zh) 4'-取代核苷的晶型、制备和应用
Bean New drug targets for HIV
KR20140144176A (ko) 잠복중인 hiv 바이러스의 재활성화에서 인게놀 유도체
HK1203872B (en) Ingenol derivatives in the reactivation of latent hiv
HK40084515A (en) Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
EP3129385A1 (en) Neosoraphens
Williams et al. ERYTHROCYTE-BASED TARGETED RELEASE ΤΟ MACROPHAGES OF AN AZIDOTHYMIDINE HOMODINUCLEOTIDE PREVENTS RETROVIRAL INFECTION
WO2019021319A1 (en) PHARMACEUTICAL COMPOSITIONS

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired